MedTrace Logo

Sienna and Sentimag in Sentinel Lymph Node Biopsy

NCT03036475 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2017-02-16

No results posted yet for this study

Summary

The aim of this study is to evaluate a new method for the localization of breast cancer sentinel lymph node using Sienna+® and Sentimag® detection in comparison to our standard techniques with radio-isotopes.

Conditions

Interventions

DEVICE

Sienna+ injection

Subcutaneous injection of Sienna+ in the morning of operation day

Sponsors & Collaborators

  • Yolanda Chan

    lead OTHER

Principal Investigators

  • Yolanda Chan, MBBS · Kwong Wah Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03036475 on ClinicalTrials.gov